NeuBase Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2016 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
NeuBase Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2016 to Q3 2023.
  • NeuBase Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2023 was -$292K, a 157% decline year-over-year.
  • NeuBase Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2023 was -$240K, a 108% decline year-over-year.
  • NeuBase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2.9M, a 21.6% decline from 2021.
  • NeuBase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $3.7M, a 28.8% decline from 2020.
  • NeuBase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2020 was $5.19M, a 42% decline from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 -$240K -$292K -$803K -157% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $563K $245K -$396K -61.8% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $959K $317K -$636K -66.8% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $1.6M -$509K -$1.3M -164% Oct 1, 2022 Dec 31, 2022 10-QT 2023-06-05
Q3 2022 $2.9M $511K -$442K -46.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $3.34M $641K +$15.9K +2.54% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $3.32M $953K +$10.7K +1.14% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $3.31M $793K -$383K -32.6% Oct 1, 2021 Dec 31, 2021 10-QT 2023-06-05
Q3 2021 $3.7M $953K -$188K -16.5% Jul 1, 2021 Sep 30, 2021 10-K 2022-12-21
Q2 2021 $3.88M $625K -$586K -48.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $4.47M $942K -$397K -29.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $4.87M $1.18M -$328K -21.8% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-11
Q3 2020 $5.19M $1.14M -$5.45M -82.7% Jul 1, 2020 Sep 30, 2020 10-K 2021-12-23
Q2 2020 $10.6M $1.21M +$391K +47.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 $10.3M $1.34M +$85.2K +6.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q4 2019 $10.2M $1.5M +$1.21M +413% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-11
Q3 2019 $8.96M $6.59M Jul 1, 2019 Sep 30, 2019 10-K 2020-12-23
Q2 2019 $820K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 $1.25M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 $293K Oct 1, 2018 Dec 31, 2018 10-Q 2020-03-26
Q2 2016 $611K Apr 1, 2016 Jun 30, 2016 10-Q 2016-08-09
Q1 2016 $1.41M Jan 1, 2016 Mar 31, 2016 10-Q 2016-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.